相关实验视频
Updated: Jun 23, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.4K
成功使用高剂量布雷克斯皮普拉治疗莱维体痴呆症精神病,没有副作用
Cho Lee1, Shang-Hsuan Shih1, Yu-Chih Shen1,2
1Department of Psychiatry, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Psychiatry and clinical psychopharmacology
|June 17, 2024
概括
较高剂量的布雷克西普拉 (每天4毫克) 可以有效地治疗患有莱维体 (DLB) 精神病的痴呆症. 这项案例研究表明,布雷克斯皮普拉是一种安全且可能有益的治疗方案,用于治疗DLB症状.
科学领域:
- 神经科学是一个神经科学.
- 老年精神病学是一门精神病学专业.
- 药理学 药理学是指药理学的学科.
背景情况:
- 勒维体痴呆症 (DLB) 是一种神经退行性疾病,其特征是认知能力下降,帕金森症和视觉幻觉.
- 在DLB中,精神病症状往往构成重大管理挑战.
- 低剂量布雷克斯皮普拉在其他痴呆症和帕金森病患者群体中对精神病有很大的前景.
研究的目的:
- 评估更高剂量的布雷克斯皮普拉在可能患有勒维体痴呆症 (DLB) 的患者中管理精神病症状的疗效和安全性.
主要方法:
- 一个71岁的病人被诊断出可能患有DLB的病例报告.
- 该患者接受了每天4毫克剂量的布雷克斯皮普拉治疗.
- 临床观察和评估精神病症状和不良影响.
主要成果:
- 患者在精神病症状方面经历了显著的改善.
- 在每天4毫克的剂量下没有观察到任何不良反应.
- 布雷克西普拉在最大每日剂量时,在这个DLB患者中表现出耐受性.
结论:
- 布雷克西普拉,即使是每天4毫克的较高剂量,也可能是治疗勒维体痴呆症 (DLB) 精神病症状的安全有效方法.
- 需要进一步的研究来证实布雷克斯皮普拉在更大的DLB队列中的疗效和安全性.
- 这一案例表明,布雷克斯皮普拉作为一种潜在的治疗选择,用于管理DLB相关的精神病.
相关概念视频
Psychosis: Goals of Pharmacotherapy
122
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
122
Psychosis and Antipsychotic Drugs: Overview
234
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
234
Drug Therapy
42
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
42
Parkinson's Disease: Treatment
255
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
255
Antipsychotic Drugs: Therapeutic Uses and Side Effects
166
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
166
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
120
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
120

